The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

Fri, 06th May 2022 19:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Mpac Group PLC - Coventry, England-based packaging company - Says trading in 2022 so far has been in line with expectations. Explains the prospects pipeline is strong and its current order book is "significantly" above the previous year. However, company notes that supply chain uncertainties and operational challenges have increased, amplified by transportation delays. Mitigation measures in place and thus company remains positive. Chief Executive Tony Steels says he expects the full-year to be in line with expectations.

----------

Primorus Investments PLC - London-based investment firm focused on small and mid cap firms in financial services, technology and natural resources - Signs a deed of amendment which extends the time for investee Alteration Earth PLC to complete its prospectus and obtain its listing on the London Stock Exchange. Date has been extended to June 6 from May 4.

----------

Arix Bioscience PLC - London-based venture capital investor in biotech firms - Receives notice Acacia Research Corp that it has increased its ownership of the company. Acacia acquires a further 646,932 shares representing 21% of Arix's share capital. Acacia also notifies Arix that it does not intend to make an offer for the company.

----------

Gunsynd PLC - London-based investment company focused on the natural resources, life sciences and alcohol sector - Gives notice to Sajawin Pty Ltd to terminate the term sheet and variation terms sheet in relation to the disposal of Gunsynd's shareholding in Oyster Oil & Gas Ltd. Gunsynd, in conjunction with other shareholders in Oyster, will now seek alternative avenues to monetise the project.

----------

Pantheon Resources PLC - London-based oil and gas company focused on Alaska - Announces that the holder of its senior unsecured convertible bonds due 2026 has exercised conversion rights for USD3.8 million. Accordingly, the remaining amount under the convertible bonds will be reduced to USD46.6 million.

----------

Open Orphan PLC - London-based pharmaceutical services company - Notes market speculation regarding its potential delisting. Confirm it has no plans to delist and says it is working with Liberum Capital to complete its due diligence.

Separately, company says its subsidiary, hVIVO, has signed a "substantial" contract with an unnamed pharmaceutical client. Contract is manufacture a virus for use in human challenge studies. Adds that virus manufacturing activities have commenced and expected to be completed by the end of the third quarter of 2022. Revenue for the manufacturing process will be recognised in 2022, company says.

----------

Insig AI PLC - London-based data science and machine learning company - Signs agreement for a GBP1.0 million convertible loan note. Note provided by Non-Executive Chair Richard Bernstein. Loan is unsecured and repayable on or before December 31. An initial tranche of GBP250,000 has been drawn down.

----------

Enwell Energy PLC - London-based oil and gas company - Says SV-31 well is currently producing at a stabilised flow rate of 2.7 million standard cubic feet per day of gas and 185 barrels per day of condensate. All operations remain suspended at the Vasyschevskoye gas and condensate field and the Svystunivsko-Chervonolutskyi exploration licence in light of Russian military action in Ukraine. Chief Executive Sergii Glazunov says: "We are very pleased with the results of the SV-31 well, which was drilled safely and successfully, and ahead of schedule. The completion of the well in the current extremely challenging environment in Ukraine is a great achievement by our team, and the strong flow rates recorded will provide a welcome boost to our overall production volumes."

----------

ImmuPharma PLC - London-based drug discovery and development company - Confirms that final preparations are underway to progress Lupuzor into a new phase three trial for lupus patients. Adds that its US partner Avion Pharmaceuticals have confirmed they are requesting final guidance from the US Food & Drug Adminstration to commence the phase three trial. Chief Executive Tim McCathy says: "Following the positive readout from the [pharmacokinetic] study, we have been working closely with the team at Avion to move Lupuzor as quickly as possible to the start of the Phase 3 trial."

----------

SDX Energy PLC - London-based oil and gas company focused on Egypt and Morocco - Completes tie-in of the SD-5X Warda well one month ahead of schedule. The company holds a 37% working interest in the well. Well is now under production test, with first gas achieved on April 27. After the initial flow period, there will be a shut-in of 12 hours followed by a main flow period of five days. Post the main flow period, the well will be shut in for 10 days to monitor the pressure build-up. Chief Executive Mark Reid says: "The well is now contributing to production and cash flow from this asset much earlier than originally anticipated... Once the long-term production profile for the well has been established, we will revise our 2022 production guidance if appropriate."

----------

CleanTech Lithium PLC - Jersey-based lithium exploration and development company focused on Chile - Reports drilling at its Laguna Verde and Francisco Basin. Two drill rigs are now in operation at the Francisco Basin. Upgrades resource estimate for Laguna Verde. Maiden resource estimate for Francisco Basin on track for the second quarter of 2022. Chief Executive Aldo Boitano says: "The resource drilling programmes, which commenced in January 2022 at Laguna Verde and in March 2022 at Francisco Basin, continue to progress well. The Francisco Basin programme has been accelerated with the addition of the second rig, bringing the total number of rigs operating across both sites to three."

----------

Caerus Mineral Resources PLC - Cyprus-based exploration & resource development company focussed on Europe - Returns "consistently anomalous" gold assay results from hand auger drilling and pitting results for the Mala pyrite dump in Cyprus. Reports peak gold grades 9.9 grams per tonne of gold, 1.3 grams per tonne of gold and 1.2 grams per tonne of gold. A total of 55 auger holes and pits return gold grades from 0.1 to 9.9 grams per tonne of gold. Chief Executive Martyn Churchouse says: "The potential gold resource in the pyrite dumps combined with the known sulphide body is an excellent start and provides the confidence we need to commit to further detailed resource development."

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2022 11:45

Open Orphan's hVIVO wins GBP14.7 million influenza study contract

(Alliance News) - Open Orphan PLC on Wednesday said it's subsidiary hVIVO signed a GBP14.7 million contract for an influenza characterisation study and a follow on influenza human challenge study.

Read more
31 May 2022 16:05

UK earnings, trading statements calendar - next 7 days

Wednesday 1 June  
Impax Asset Management Group PLCHalf Year Results
Dr Martens PLCFull Year Results
Thursday 2 June  
no events scheduled 
Friday  3 June  
no events scheduled  
Monday 6 June  
Atrato Onsite Energy PLCHalf Year Results
Empiric Student Property PLCTrading Statement
Jadestone Energy PLCFull Year Results
Tuesday 7 June  
Gooch & Housego PLCHalf Year Results
LXi REIT PLCFull Year Results
NewRiver REIT PLCFull Year Results
Open Orphan PLCFull Year Results
Schroder Real Estate Investment Trust LtdFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
18 May 2022 16:43

Open Orphan's hVIVO wins GBP7.3 million influenza study contract

(Alliance News) - Open Orphan PLC on Wednesday said its subsidiary hVIVO Ltd has signed a GBP7.3 million contract.

Read more
18 May 2022 15:15

Open Orphan wins £7.3m human flu study contract

(Sharecast News) - Specialist contract research organisation Open Orphan announced on Wednesday that its hVIVO subsidiary has signed a £7.3m flu human challenge study contract with an unnamed biotechnology company, to test its antiviral product using hVIVO's influenza human challenge study model.

Read more
5 May 2022 14:53

IN BRIEF: Open Oprhan wins contract for vaccine field site study

Open Orphan PLC - London-based pharmaceutical services - Subsidiary hVIVO is awarded new study with existing unnamed pharmacetical client to act as vaccination site for the client's respiratory syncytial virus vaccine candidate. hVIVO's specialist arm FluCamp will recruit 60 healthy volunteers to the new site clinic at Plumbers Row where trials will take place.

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
1 Apr 2022 20:23

IN BRIEF: Open Orphan Covid study results published in Nature Medicine

Open Orphan PLC - London-based pharmaceutical services - Says Thursday that results from the world's first Covid-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. Says study showed the SARS-CoV-2 human challenge was safe in healthy young adults and provided insights into the course of Covid-19 infection with potential positive public health implications. With the characterisation study disease modelling data completed, and human challenge model established, Open Orphan says it should be able to conduct Covid-19 human challenge studies in 2022.

Read more
25 Mar 2022 14:10

IN BRIEF: Open Orphan wins GBP5 million human challenge study pact

Open Orphan PLC - London-based pharmaceutical services firm - Says its subsidiary, hVIVO, wins contract with a European biotechnology company for a human challenge study. The GBP5 million contract with a European biotech seeks to test hVIVO's intravenous antiviral candidate. The study on the respiratory syncytial virus is expected to commence this year. Revenue from the deal will be recognised across 2022 and 2023.

Read more
25 Mar 2022 09:39

Open Orphan wins £5m contract for human study in RSV

(Sharecast News) - Open Orphan announced on Friday that its hVIVO subsidiary has signed a £5m respiratory syncytial virus (RSV) human challenge study contract with an unnamed European biotechnology company, to test its intravenous antiviral candidate.

Read more
8 Mar 2022 19:37

IN BRIEF: Open Orphan expects to report profitable 2021 performance

Open Orphan PLC - London-based pharmaceutical services - For 2021, expects to report earnings before interest, tax, depreciation and amortisation, on revenue which is set to be GBP40 million, up from GBP20.6 million in 2020. For 2022, the company is targeting GBP50 million in non-Covid work revenue.

Read more
24 Feb 2022 15:24

Open Orphan appoints Mo Khan as its new chief executive

(Sharecast News) - Contract research organisation Open Orphan announced the appointment of Yamin 'Mo' Khan as its chief executive officer on Thursday, with immediate effect.

Read more
24 Feb 2022 14:48

IN BRIEF: Open Orphan non-exec Mo Khan switches to chief executive

Open Orphan PLC - London-based pharmaceutical services - Moves Non-Executive Director Mo Khan to chief executive officer, effective immediately. Khan had joined the Open Orphan board back in October. The company notes he has 25 years of clinical research experience. Cathal Friel remains executive chair, while Open Orphan will aim to find a new independent non-executive director within the next six months.

Read more
22 Feb 2022 21:57

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
17 Feb 2022 20:13

IN BRIEF: Positive results from Open Orphan human challenge study

Open Orphan PLC - pharmaceutical services provider - Sees positive results from a human challenge study assessing its respiratory syncytial virus antiviral candidate, EDP-938. Says results from the study have been published in The New England Journal of Medicine. hVIVO, a subsidiary of Open Orphan, conducted the Phase 2a, double-blind, placebo-controlled trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.